Adamis Pharmaceuticals Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADMP research report →
About the company
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19.
- CEO
- Ebrahim Versi
- IPO
- 1995
- Employees
- 11
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $7.25M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
- Gross Margin
- -60.93%
- Op Margin
- -526.88%
- Net Margin
- -556.72%
- ROE
- -209.88%
- ROIC
- 20462.31%
- Revenue
- $4.76M · 115.34%
- Net Income
- $-26,199,406 · 24.28%
- EPS
- $-12.24 · 27.14%
- Op Income
- $-25,058,966
- FCF YoY
- 31.86%
- 52W High
- $21.70
- 52W Low
- $0.45
- 50D MA
- $0.90
- 200D MA
- $6.11
- Beta
- 1.28
- Avg Volume
- 3.11M
Get TickerSpark's AI analysis on ADMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 23, 23 | Dorbin John W. Jr. | other | 70,000 |
| Oct 23, 23 | Dorbin John W. Jr. | other | 0 |
| Oct 16, 23 | COHEN SETH | other | 151,416 |
| Oct 16, 23 | COHEN SETH | other | 0 |
| Sep 15, 23 | Versi Ebrahim | other | 729,200 |
| Sep 15, 23 | Versi Ebrahim | other | 729.2 |
| May 25, 23 | Versi Ebrahim | other | 177,194 |
| May 25, 23 | Versi Ebrahim | other | 20,577 |
| May 25, 23 | Versi Ebrahim | other | 8,745 |
| May 25, 23 | Versi Ebrahim | other | 1,941.2 |
Our ADMP coverage
Recent articles, reports, and earnings notes.
No research on ADMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADMP report →Similar companies
Peers in the same neighborhood.